Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Jiaxin Niu"'
Autor:
Tomislav Dragovich, Ramez Awad, Naveen Yarlagadda, Mark Gimbel, Sunilkumar Kakadia, Madappa N. Kundranda, Jiaxin Niu, Lida A. Mina, Fade Mahmoud, Boris G. Naraev
Publikováno v:
OncoTargets and therapy
Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to